Indication
DDD
3 clinical trials
1 product
Product
PegcetacoplanClinical trial
US Early Access Program for the Treatment of Patients With C3 Glomerulopathy or Primary Immune-Complex Membranoproliferative Glomerulonephritis With PegcetacoplanStatus:
Clinical trial
A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative GlomerulonephritisStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative GlomerulonephritisStatus: Active (not recruiting), Estimated PCD: 2027-07-01